Home › Endometrial Cancer › Alabama
Endometrial Cancer clinical trials in Alabama
19 studies for Endometrial Cancer are looking for participants at sites in Alabama.
Cities in Alabama
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
- University of Alabama at Birmingham Cancer Center, Birmingham
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 28, 2026 · NCT05256225Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- University of Alabama at Birmingham Cancer Center, Birmingham
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 28, 2026 · NCT05112601Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Alabama at Birmingham Cancer Center, Birmingham
- University of South Alabama Mitchell Cancer Institute, Mobile
RecruitingPhase 2
All ages · All sexes · Updated Sep 28, 2026 · NCT05564377Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- University of Alabama_6th Ave, Birmingham
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Sep 25, 2026 · NCT03564340DESTINY-PANTUMOUR04
- Research Site, Birmingham
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- University of Alabama at Birmingham Cancer Center, Birmingham
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 25, 2026 · NCT07198074A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- University of South Alabama, Mitchell Cancer Institute ( Site 6033), Mobile
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 17, 2026 · NCT06952504ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- University of Alabama at Birmingham, Birmingham
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT05059444Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Alabama Birmingham, Birmingham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06293898Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- USAH Mitchell Cancer Inst, Mobile
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 9, 2026 · NCT07166094A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06760819Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital of Alabama, Birmingham
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- University of Alabama at Birmingham, Birmingham
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT04657068The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons
- University of Alabama at Birmingham, Birmingham
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 99 · Women · Updated Jul 29, 2026 · NCT03538665A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- University of Alabama at Birmingham, Birmingham
- University of Alabama at Birmingham, IDS Pharmacy, Birmingham
- University of Alabama at Birmingham, Birmingham
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT05208762Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- 004, Birmingham
RecruitingPhase 2
Ages 18 and older · Women · Updated Jul 16, 2026 · NCT06906341Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
- O'Neal Comprehensive Cancer Center at UAB, Birmingham
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Apr 15, 2026 · NCT05559879177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- Dothan Hematology & Oncology, Dothan
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Mar 27, 2026 · NCT07189871SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Birmingham
- Massive Bio SYNERGY-AI site, Mobile
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.